Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.

Unlabelled: The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-naïve patients from 133 centers were treated with PEG-IFN alfa-2b (1.5 μg/kg/week) plus RBV (800-1,400 mg/day).

Antitumor features of Bacillus oligonitrophilus KU-1 strain.

Chemotherapy and radiotherapy remain mostly palliative methods for metastatic cancer treatment. Limitations in efficacy and safety of established treatments continue to underline the need for improved treatments for malignancy. Results with some probiotics with antitumor activity have been promising.